{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T03:09:40Z","timestamp":1783739380030,"version":"3.55.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,22]]},"DOI":"10.7759\/cureus.95192","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T03:31:55Z","timestamp":1761190315000},"source":"Crossref","is-referenced-by-count":1,"title":["Challenges and Efficacy of Amikacin Liposome Inhalation in Real-World Refractory Mycobacterium avium Complex Pulmonary Disease"],"prefix":"10.7759","author":[{"given":"Toyoshi","family":"Yanagihara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Osaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takato","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Shundo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Ebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3201\/eid2206.151086","article-title":"Epidemiology of pulmonary nontuberculous mycobacterial disease, Japan","volume":"22","author":"Namkoong H","year":"2016","unstructured":"Namkoong H, Kurashima A, Morimoto K, Hoshino Y, Hasegawa N, Ato M, Mitarai S. Epidemiology of pulmonary nontuberculous mycobacterial disease, Japan. Emerg Infect Dis. 2016, 22:1116-7. 10.3201\/eid2206.151086","journal-title":"Emerg Infect Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200604-571ST","article-title":"An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","author":"Griffith DE","year":"2007","unstructured":"Griffith DE, Aksamit T, Brown-Elliott BA, et al.. An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007, 175:367-416. 10.1164\/rccm.200604-571ST","journal-title":"Am J Respir Crit Care Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0b013e3283511a64","article-title":"Therapy of refractory nontuberculous mycobacterial lung disease","volume":"25","author":"Griffith DE","year":"2012","unstructured":"Griffith DE, Aksamit TR. Therapy of refractory nontuberculous mycobacterial lung disease. Curr Opin Infect Dis. 2012, 25:218-27. 10.1097\/QCO.0b013e3283511a64","journal-title":"Curr Opin Infect Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201807-1318OC","article-title":"Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex (CONVERT) a prospective, open-label, randomized study","volume":"198","author":"Griffith DE","year":"2018","unstructured":"Griffith DE, Eagle G, Thomson R, et al.. Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex (CONVERT) a prospective, open-label, randomized study. Am J Respir Crit Care Med. 2018, 198:1559-69. 10.1164\/rccm.201807-1318OC","journal-title":"Am J Respir Crit Care Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.resinv.2023.12.012","article-title":"Amikacin liposome inhalation suspension for Mycobacterium avium complex pulmonary disease: a subgroup analysis of Japanese patients in the randomized, phase 3, CONVERT study","volume":"62","author":"Morimoto K","year":"2024","unstructured":"Morimoto K, Nonaka M, Yamazaki Y, et al.. Amikacin liposome inhalation suspension for Mycobacterium avium complex pulmonary disease: a subgroup analysis of Japanese patients in the randomized, phase 3, CONVERT study. Respir Investig. 2024, 62:284-90. 10.1016\/j.resinv.2023.12.012","journal-title":"Respir Investig"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa241","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"71","author":"Daley CL","year":"2020","unstructured":"Daley CL, Iaccarino JM, Lange C, et al.. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline. Clin Infect Dis. 2020, 71:e1-e36. 10.1093\/cid\/ciaa241","journal-title":"Clin Infect Dis"},{"key":"ref7","article-title":"","year":"2025","unstructured":"Guide to Mycobacterial Testing 2025 [Book in Japanese]. Nankodo, Tokyo, Japan; 2025. https.\/\/www.nankodo.co.jp\/g\/g9784524216017\/?srsltid=AfmBOopMsmIxYhuNrZPwWVWgSVjCVTNj-sq8y6JKUfgFrrAP65YVtfBO."},{"key":"ref8","article-title":"","year":"2017","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. U.S. Department of Health and Human Services, Bethesda (MD); 2017. https.\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-5x7.pdf."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-024-03261-w","article-title":"Effectiveness of Amikacin liposome inhalation suspension for refractory Mycobacterium avium complex pulmonary disease at 6\u00a0months post initiation","volume":"24","author":"Urabe N","year":"2024","unstructured":"Urabe N, Sakamoto S, Tokita N, et al.. Effectiveness of Amikacin liposome inhalation suspension for refractory Mycobacterium avium complex pulmonary disease at 6\u00a0months post initiation. BMC Pulm Med. 2024, 24:442. 10.1186\/s12890-024-03261-w","journal-title":"BMC Pulm Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf118","article-title":"Effects of amikacin liposome inhalation suspension and amikacin resistance development in patients with refractory mycobacterium avium complex pulmonary disease","volume":"12","author":"Kurahara Y","year":"2025","unstructured":"Kurahara Y, Yoshida S, Osugi A, et al.. Effects of amikacin liposome inhalation suspension and amikacin resistance development in patients with refractory mycobacterium avium complex pulmonary disease. Open Forum Infect Dis. 2025, 12:ofaf118. 10.1093\/ofid\/ofaf118","journal-title":"Open Forum Infect Dis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.23.0275","article-title":"Management of dysphonia caused by amikacin liposome inhalation in M. avium complex pulmonary disease","volume":"27","author":"Kurahara Y","year":"2023","unstructured":"Kurahara Y, Kanaoka K, Tanaka Y, et al.. Management of dysphonia caused by amikacin liposome inhalation in M. avium complex pulmonary disease. Int J Tuberc Lung Dis. 2023, 27:872-3. 10.5588\/ijtld.23.0275","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa079","article-title":"Clinical management of respiratory adverse events associated with amikacin liposome inhalation suspension: Results from a patient survey","volume":"7","author":"Swenson C","year":"2020","unstructured":"Swenson C, Lapinel NC, Ali J. Clinical management of respiratory adverse events associated with amikacin liposome inhalation suspension: Results from a patient survey. Open Forum Infect Dis. 2020, 7:ofaa079. 10.1093\/ofid\/ofaa079","journal-title":"Open Forum Infect Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.5350","article-title":"Laryngitis after inhalation of liposomal amikacin","volume":"10","author":"Morita A","year":"2022","unstructured":"Morita A, Namkoong H, Hosoya M, Hasegawa N. Laryngitis after inhalation of liposomal amikacin. Clin Case Rep. 2022, 10:e05350. 10.1002\/ccr3.5350","journal-title":"Clin Case Rep"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S373783","article-title":"Early-phase adverse effects and management of liposomal amikacin inhalation for refractory Mycobacterium avium complex lung disease in real-world settings","volume":"15","author":"Morita A","year":"2022","unstructured":"Morita A, Namkoong H, Yagi K, et al.. Early-phase adverse effects and management of liposomal amikacin inhalation for refractory Mycobacterium avium complex lung disease in real-world settings. Infect Drug Resist. 2022, 15:4001-11. 10.2147\/IDR.S373783","journal-title":"Infect Drug Resist"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.56622","article-title":"Amikacin liposome inhalation suspension in the real-world management of refractory Mycobacterium avium complex pulmonary disease","volume":"16","author":"Yanagihara T","year":"2024","unstructured":"Yanagihara T, Ogata H, Mori A, et al.. Amikacin liposome inhalation suspension in the real-world management of refractory Mycobacterium avium complex pulmonary disease. Cureus. 2024, 16:e56622. 10.7759\/cureus.56622","journal-title":"Cureus"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-021-01010-z","article-title":"Amikacin liposome inhalation suspension in refractory Mycobacterium avium complex lung disease: a profile of its use","volume":"41","author":"Hoy SM","year":"2021","unstructured":"Hoy SM. Amikacin liposome inhalation suspension in refractory Mycobacterium avium complex lung disease: a profile of its use. Clin Drug Investig. 2021, 41:405-12. 10.1007\/s40261-021-01010-z","journal-title":"Clin Drug Investig"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/425910-challenges-and-efficacy-of-amikacin-liposome-inhalation-in-real-world-refractory-mycobacterium-avium-complex-pulmonary-disease","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T03:31:57Z","timestamp":1761190317000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/425910-challenges-and-efficacy-of-amikacin-liposome-inhalation-in-real-world-refractory-mycobacterium-avium-complex-pulmonary-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.95192","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,22]]}}}